Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | RARG | P13631 | 2/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150571 | 0.86 | VCAM1 (0.39) | RXRAPPARGRARGVCAM1ELANE | |
| SCHEMBL2343577 | 0.84 | TSHR (0.41) | RXRAHPGDTSHRRAB9A | |
| SCHEMBL29728524 | 0.77 | RXRA (0.35) | RXRAPPARGRARGVCAM1ELANE | |
| SCHEMBL29481500 | 0.75 | HPGD (0.38) | RXRAPPARGRARGHPGDTSHR | |
| SCHEMBL28719488 | 0.75 | HPGD (0.38) | RXRAPPARGRARGHPGDTSHR | |
| SCHEMBL7223876 | 0.71 | ALDH1A1 (0.52) | HPGDTSHRRAB9A | |
| SCHEMBL7225330 | 0.70 | NLRP3 (0.50) | HPGDTSHRRAB9A | |
| SCHEMBL3292544 | 0.70 | VCAM1 (0.39) | RXRAPPARGRARGVCAM1ELANE | |
| SCHEMBL28188800 | 0.70 | ALDH1A1 (0.38) | HPGDTSHRRAB9A | |
| SCHEMBL29728510 | 0.69 | HTR1D (0.39) | RXRAHPGDTSHRRAB9AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945572-B | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia | 周美吟 | 2025-01-28 | — | — | CN | disclosed |